| The ALLgorithMM: How to define the hemodilution of bone marrow samples in lymphoproliferative diseases I Vigliotta, S Armuzzi, M Barone, V Solli, I Pistis, E Borsi, B Taurisano, ... Frontiers in Oncology 12, 1001048, 2022 | 3 | 2022 |
| Identification of a maturation plasma cell index through a highly sensitive droplet digital PCR assay gene expression signature validation in newly diagnosed multiple myeloma … M Martello, V Solli, R Termini, A Kanapari, D Remondini, E Borsi, A Poletti, ... International Journal of Molecular Sciences 23 (20), 12450, 2022 | 1 | 2022 |
| BoBafit : A copy number clustering tool designed to refit and recalibrate the baseline region of tumors' profiles G Mazzocchetti, A Poletti, V Solli, E Borsi, M Martello, I Vigliotta, S Armuzzi, ... Computational and Structural Biotechnology Journal 20, 3718-3728, 2022 | 1 | 2022 |
| OAB-059: Towards a comprehensive multimodal minimal residual disease assessment in multiple myeloma: the role of circulating cell-free DNA to define the extent of disease spreading M Martello, A Poletti, E Borsi, B Taurisano, V Solli, S Armuzzi, ... Clinical Lymphoma Myeloma and Leukemia 21, S37, 2021 | 1 | 2021 |
| Interference of daratumumab and efficacy of plerixafor on haematopoietic stem cells in Multiple Myeloma patients F Bigi, P Tacchetti, A Giorgi, G Mazzocchetti, V Solli, S Barbato, ... Frontiers in Hematology 3, 1386973, 2024 | | 2024 |
| Single-Cell DNA Sequencing Reveals an Evolutionary Pattern of CHIP in Transplant Eligible Multiple Myeloma Patients E Borsi, I Vigliotta, A Poletti, G Mazzocchetti, V Solli, L Zazzeroni, ... Cells 13 (8), 657, 2024 | | 2024 |
| Multi-dimensional scaling techniques unveiled gain1q&loss13q co-occurrence in Multiple Myeloma patients with specific genomic, transcriptional and adverse clinical features C Terragna, A Poletti, V Solli, M Martello, E Zamagni, L Pantani, E Borsi, ... Nature Communications 15 (1), 1551, 2024 | | 2024 |
| T Cell/Natural Killer (NK) Cell Transcriptional Profiles Are Associated with Response to Gilteritinib in FLT3-Mutated Acute Myeloid Leukemia J Nanni, J Vadakekolathu, L Bandini, S Bruno, L Zannoni, C Sartor, ... Blood 142 (Supplement 1), 2947-2947, 2023 | | 2023 |
| High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients E Borsi, G Mazzocchetti, AF Dico, I Vigliotta, M Martello, A Poletti, V Solli, ... Clinical and Experimental Medicine 23 (8), 5227-5239, 2023 | | 2023 |
| High Level of Circulating Tumour DNA at Diagnosis Correlates With Disease Spreading and Defines Multiple Myeloma Patients With Poor Prognosis M Martello, B Taurisano, V Solli, G Mazzocchetti, A Poletti, E Borsi, ... The Journal of Liquid Biopsy 1, 2023 | | 2023 |
| P-068 Implementation of next generation sequencing as best tool for routine evaluation of minimal residual disease in the daily practice of multiple myeloma patients S Armuzzi, M Martello, B Taurisano, I Vigliotta, I Pistis, V Solli, E Borsi, ... Clinical Lymphoma Myeloma and Leukemia 23, S72, 2023 | | 2023 |
| P-370 CoMMsol: a machine learning model for outcome-specific copy number alterations' clonality cut-offs definition in multiple myeloma V Solli, A Kanapari, G Mazzocchetti, A Poletti, I Vigliotta, M Martello, ... Clinical Lymphoma Myeloma and Leukemia 23, S243-S244, 2023 | | 2023 |
| OA-22 TiMMing: developing an innovative suite of bioinformatic tools to harmonize and track the origin of copy number alterations in the evolutionary history of multiple myeloma A Poletti, JB Alberge, G Mazzocchetti, V Solli, A Kanapari, E Borsi, ... Clinical Lymphoma Myeloma and Leukemia 23, S14, 2023 | | 2023 |
| P860: CIRCULATING MULTIPLE MYELOMA CELLS (CMMCS) AS PROGNOSTIC FACTOR AND MINIMAL RESIDUAL DISEASE MARKER IN MM AND SMOULDERING MM PATIENTS I Vigliotta, V Solli, S Armuzzi, A Kanapari, A Poletti, B Taurisano, I Pistis, ... HemaSphere 7 (S3), e182325c, 2023 | | 2023 |
| A Methodologically Updated De-Novo Extraction of Copy Number Signatures in Multiple Myeloma: Clinical Significance and Putative Aetiologies A Poletti, S Delle Vedove, G Mazzocchetti, V Solli, A Kanapari, E Borsi, ... Blood 140 (Supplement 1), 1559-1560, 2022 | | 2022 |
| P-077: Multiple myeloma genomic landscape explored by dimensional scaling technique highlights the presence of 1q&13+ patients with specific genomic, transcriptional and … C Terragna, A Poletti, V Solli, M Martello, E Borsi, E Zamagni, L Pantani, ... Clinical Lymphoma Myeloma and Leukemia 22, S77-S78, 2022 | | 2022 |
| S174: HIGH LEVEL OF CIRCULATING TUMOUR DNA AT DIAGNOSIS CORRELATES WITH DISEASE SPREADING AND DEFINES MULTIPLE MYELOMA PATIENTS WITH POOR PROGNOSIS M Martello, A Poletti, D Bezzi, E Borsi, B Taurisano, V Solli, S Armuzzi, ... HemaSphere 6, 75-76, 2022 | | 2022 |
| COMPARISON BETWEEN METHODS TO CHECK THE QUALITY OF BONE MARROW ASPIRATE SAMPLES FOR THE MINIMAL RESIDUAL DISEASE EVALUATION IN MULTIPLE MYELOMA AND ACUTE LYMPHOBLASTIC LEUKEMIA I Vigliotta, S Armuzzi, M Barone, V Solli, I Pistis, E Borsi, M Martello, ... HAEMATOLOGICA 107, 37-37, 2022 | | 2022 |
| DESIGN AND VALIDATION OF A CUSTOM NGS TARGETED PANEL, MM-UMA (UNIQUE MOLECULAR ASSAY)-PANEL, TO IDENTIFY GENOMIC ABNORMALITIES IN MULTIPLE MYELOMA PATIENTS: INTRA-LABORATORY … B Taurisano, M Martello, A Poletti, B Ziccheddu, G Mazzocchetti, V Solli, ... HAEMATOLOGICA 107, 27-27, 2022 | | 2022 |
| HOW TO GUARANTEE THE CORRECT MULTIPLE MYELOMA PATIENTS'CLINICAL STRATIFICATION BY UN-BIASED COPY NUMBER ESTIMATION WITH BOBAFIT G Mazzocchetti, A Poletti, V Solli, E Borsi, M Martello, I Vigliotta, S Armuzzi, ... HAEMATOLOGICA 107, 29-30, 2022 | | 2022 |
